Novel therapeutic target against prostate cancer
Current treatment options for prostate cancer include the use of androgen deprivation therapies to block tumour growth. However, the tumours often become castration-resistant. Approximately 25 % of the prostate cancer patients with castration-resistant disease treated with antiandrogens develop a form of prostate cancer that is completely independent of androgen receptor signalling, which promotes tumour growth. Analyses of the pathology and genomics of these patient tumours have identified that the tumour cells adapt cancer stem cell and neuronal cell characteristics. The EU-funded TARNEPC project aims to characterise a novel therapeutic target against aggressive treatment-resistant neuroendocrine prostate cancer.
Fields of science
Call for proposal
See other projects for this call